European commission grants marketing authorization for jyseleca® ▼ (filgotinib) for the treatment of adults with moderate to severe active rheumatoid arthritis

Gilead sciences, inc. (nasdaq: gild) and galapagos nv (euronext & nasdaq: glpg) today announced that the european commission (ec) has granted mark

ADES Ratings Summary

ADES Quant Ranking